How many insider trades does FilingIQ track for PBYI?

FilingIQ tracks 414 Form 4 insider transactions for PBYI (PUMA BIOTECHNOLOGY, INC.), covering filings from Apr 9, 2014 onwards. 6 of those were filed in the last 90 days.

Are PBYI insiders net buyers or net sellers?

Across the full Form 4 history for PBYI, 2 transactions (0%) were open-market purchases and 272 (66%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PBYI insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PBYI in?

PUMA BIOTECHNOLOGY, INC. (PBYI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $337.62M.

PBYI insider trading

NasdaqGS Healthcare

PUMA BIOTECHNOLOGY, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

414

Last 90 days

Buys / sells

0% / 66%

Market cap

$337.62M

About PUMA BIOTECHNOLOGY, INC.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Company website: www.pumabiotechnology.com

PBYI insider activity at a glance

FilingIQ has scored 414 insider transactions for PBYI since Apr 9, 2014. The most recent filing in our index is dated Feb 18, 2026.

Across the full history, 2 open-market purchases and 272 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PBYI insider trades is 56.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PBYI trades on FilingIQ Raw filings on SEC EDGAR

Latest PBYI Form 4 filings

NOUGUES MAXIMO F Chief Financial Officer

S Jul 3, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for PBYI?: FilingIQ tracks 414 Form 4 insider transactions for PBYI (PUMA BIOTECHNOLOGY, INC.), covering filings from Apr 9, 2014 onwards. 6 of those were filed in the last 90 days.
Are PBYI insiders net buyers or net sellers?: Across the full Form 4 history for PBYI, 2 transactions (0%) were open-market purchases and 272 (66%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PBYI insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PBYI in?: PUMA BIOTECHNOLOGY, INC. (PBYI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $337.62M.

Methodology & sources

Every PBYI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.